Fulltext

Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study

Mallion, Jean-Michel ; Chamontin, Bernard ; Asmar, Roland ; Leeuw, Peter Wilhelmus De ; O'Brien, Eoin ; Duprez, Daniel ; O'Rourke, Michael F. ; Rahn, Karl-Heinz ; Romero, Ramon ; Battegay, Edouard ; Hitzenberger, Gerhart ; Safar, Michel E.

In: American Journal of Hypertension, 2004, vol. 17, no. 3, p. 245-251

Ajouter à la liste personnelle
    Titre
    • Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study
    Auteur
    • Mallion, Jean-Michel. Cardiologie et Hypertension Artérielle, CHU Grenoble, France
    • Chamontin, Bernard. Hôpital Purpan, Toulouse, France
    • Asmar, Roland. Hôpital Broussais, Paris, France
    • Leeuw, Peter Wilhelmus De. Academisch Ziekenhuis Maastricht, Maastricht, The Netherlands
    • O'Brien, Eoin. Blood Pressure Unit, Beaumont Hospital, and RCSI Medical School, Dublin, Ireland
    • Duprez, Daniel. Universitair Ziekenhuis Gent, Gent, Belgium
    • O'Rourke, Michael F.. Saint Vincent's Hospital, Darlinghurst, Australia
    • Rahn, Karl-Heinz. Medizinische Poliklinik, University of Münster, Münster, Germany
    • Romero, Ramon. Hospital Germans Trias y Pujol, Badalona, Spain
    • Battegay, Edouard. Medizinische Universitäts Poliklinik, Basel, Switzerland
    • Hitzenberger, Gerhart. Institut für Hypertoniker, Wien, Austria
    • Safar, Michel E.. Hôpital Broussais, Paris, France
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:296330
    Summary
    Background: Circadian blood pressure (BP) measurements provide more information on hypertensive complications than office BP measurements. The purpose of this study was to analyze the efficacy of the first-line combination of perindopril 2 mg plus indapamide 0.625 mg versus atenolol 50 mg on BP parameters and variability over 24 h in patients with hypertension. Methods: A double-blind, randomized, controlled, 12-month study comparing perindopril/indapamide and atenolol was performed in 201 patients (age 55.0 years) with uncomplicated sustained essential hypertension. Ambulatory BP measurements (ABPM) were done every 15 min over 24 h. Results: After 1 year of treatment, the decrease in systolic BP was significantly greater for perindopril/indapamide than for atenolol during the entire 24-h period (-13.8 ν −9.2 mm Hg), the daytime and the nighttime periods (P < .01). Diastolic blood pressure (DBP) variations were comparable for the two groups (−7.2 ν −8.3 mm Hg, NS). Pulse pressure (PP) reduction was also significantly greater for perindopril/indapamide than for atenolol (for the whole 24 h, −6.6 ν −0.9 mm Hg, P < .001). The through to peak (T/P) BP ratio and the smoothness index were comparable in the two groups for DBP. For systolic blood pressure (SBP), higher values of the T/P ratio (0.80 ν 0.59) and the smoothness index (1.45 ν 0.98; P < .02) were achieved for the perindopril/indapamide combination than for atenolol. Conclusions: The perindopril/indapamide first-line combination decreased SBP and PP more effectively than atenolol. Moreover, the BP control effect was smooth and consistent throughout the 24-h dosing interval and BP reduction variability was lower than the one induced by atenolol